Betz Stephen F. 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Dec 18, 2024
Insider Transaction Report
Form 4
Betz Stephen F.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-12-16−2,331→ 180,039 totalExercise: $1.91Exp: 2028-03-16→ Common Stock (2,331 underlying) - Exercise/Conversion
Common Stock
2024-12-16$1.91/sh+2,331$4,452→ 71,358 total
Footnotes (1)
- [F1]1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.